Josh Jackson (Detroit Pistons) with an and one vs the Philadelphia 76ers, 01/23/2021
Josh Jackson (Detroit Pistons) with an and one vs the Philadelphia 76ers, 01/23/2021
The "Tour Operator Software Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Component, Enterprise Size, and Subscription Type" report has been added to ResearchAndMarkets.com's offering.
The suspension, which includes other goods, covers tariffs that were imposed in a row over Airbus subsidies.
LONDON — Amazon has opened a cashier-free supermarket in London, its first bricks and mortar expansion outside the U.S. as the company bets on strong demand for its contactless shops. The online retailing giant opened the doors to its Amazon Fresh shop in West London's Ealing neighbourhood on Thursday, in what it said will be the first in a wave of shops in the British capital using its automated checkout technology. Shoppers use a smartphone app to scan a QR code so they can enter the store. They can fill their shopping bags with milk, eggs or other groceries while cameras and sensors track what’s taken off shelves. Purchases are charged to an Amazon account after leaving and a receipt sent by email. There's no need to wait in line to pay at the checkout, a feature that has more appeal after the pandemic highlighted the need for social distancing. Amazon already operates 26 cashier-free convenience stores in the U.S. under the Amazon Go brand and two larger supermarkets called Amazon Go Grocery. As part of its U.K. launch, Amazon also unveiled its new private label food brand, by Amazon. The Associated Press
Parents of girls released by kidnappers had thrown stones at officials during the reunion ceremony.
• Epsolay® and Twyneo® PDUFA goal dates set for April 26, 2021 and August 1, 2021 respectively • Top-line generic product revenue of $8.7 million in fiscal 2020 • Signed additional generic product collaboration agreements with Perrigo, bringing the number of collaborations between the companies to 12 NESS ZIONA, Israel, March 04, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the full year ended December 31, 2020 and provided corporate updates. “I am very pleased with the major milestones that were achieved by Sol-Gel last year. After announcing positive data from Phase 3 trials of Epsolay and Twyneo and submitting NDAs to the FDA within guided timelines, 2020 was highlighted by positive acceptances of both NDAs and allocated PDUFA dates,” commented Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel. “Given the competitive landscape of the dermatology market and the significant capital that would be needed to directly commercialize our products, our current operational model assumes we will partner with a dermatology company that has a strong market presence. This would enable us to capture market share more quickly without the need to invest in building our own marketing and sales force and would allow us to further invest in the development of our pipeline of products with larger potential markets,” continued Dr. Seri-Levy. Corporate Highlights and Recent Developments Sol-Gel announced the U.S. Food and Drug Administration’s (FDA) acceptance of New Drug Application (NDA) for Epsolay (benzoyl peroxide, 5%, cream) with a Prescription Drug User Fee Act (PDUFA) goal date set for April 26, 2021. If approved, Epsolay has the potential to be the first FDA-approved, single-agent benzoyl peroxide prescription drug product for the treatment of inflammatory lesions of rosacea.Sol-Gel announced FDA acceptance of NDA for Twyneo (benzoyl peroxide, 3%, and tretinoin, 0.1%, cream) with a PDUFA goal date set for August 1, 2021. If approved, Twyneo has the potential to be the first FDA-approved acne treatment that contains fixed-dose combination of benzoyl peroxide and tretinoin.Sol-Gel is in discussions with potential partners regarding the commercialization of Epsolay and Twyneo in the United States to occur if the product candidates receive regulatory approval from the FDA.In preparation for commercial launch of proprietary products the Company has opened a US headquarters in Whippany, NJ.Sol-Gel was informed by its collaboration partner that the launch of an FDA-approved generic drug is expected in the second quarter of 2021. Annual sales of the brand name product exceeded $180 million in the United States in 2019.In 2020, Sol-Gel signed four additional collaboration agreements with Perrigo for the development, manufacture, and commercialization of new generic product candidates, bringing the total number of collaborations between the companies to 12.Pre-clinical testing of erlotinib (an epidermal growth factor receptor inhibitor), tapinarof (an investigational aryl hydrocarbon receptor modulator), and roflumilast (an investigational phosphodiesterase 4 inhibitor) is progressing for various new pharmaceutical indications. A total of 25 provisional patent applications for these project candidates have been submitted to date.The enrollment of patients in the Phase 1 proof-of-concept study with SGT-210 (erlotinib gel) in patients with palmoplantar keratoderma has been slowed by the COVID-19 pandemic. The Company expects to report top-line data in the third quarter of 2021.In 2020, the Company completed financings totaling $28.0 million in gross proceeds, including the proceeds of the February underwritten public offering of $23.0 million and from the $5.0 million invested in April by Sol-Gel’s controlling shareholder, M. Arkin Dermatology Ltd. Financial Results for the Year Ended December 31, 2020 Revenue in 2020 was $8.8 million. The revenue was mainly due to sales of a generic product from a collaboration arrangement with Perrigo. Research and development expenses were $27.9 million in 2020 compared to $40.6 million during the same period in 2019. The decrease of $12.7 million was mainly attributed to a decrease of $17.9 million in clinical trial expenses, mainly due to the completion of the clinical trials of Epsolay and Twyneo towards the end of 2019, a decrease of $0.4 million in other expenses, mainly due to the purchase of raw material for manufacturing, partially offset by an increase of $5.4 million in manufacturing expenses. General and administrative expenses were $11.1 million in 2020 compared to $8.3 million in 2019. The increase of $2.8 million was mainly attributed to an increase of $3.0 million in commercialization expenses and an increase of $0.4 million in patent related expenses, partially offset by a decrease of $0.7 million in stock based compensation expenses. Sol-Gel reported a loss of $29.3 million for the full year of 2020 compared to loss of $24.6 million for the same period in 2019. As of December 31, 2020, Sol-Gel had $28.5 million in cash, cash equivalents and deposits, and $21.7 million in marketable securities for a total balance of $50.2 million. Sol-Gel expects its existing cash resources will enable funding of operational and capital expenditure requirements into the third quarter of 2022. About Sol-Gel Technologies Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company’s pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets – erlotinib, tapinarof and roflumilast – currently being tested for various pharmaceutical indications. For additional information, please visit www.sol-gel.com. About Epsolay® Epsolay is an investigational topical cream containing encapsulated benzoyl peroxide, 5%, for the treatment of papulopustular rosacea. Epsolay utilizes a patented technology process to encapsulate benzoyl peroxide within silica-based microcapsules to create a barrier between the medication and the skin. The slow migration of medication from the microcapsules is designed to deliver an effective dose of benzoyl peroxide onto the skin, while reducing the ability of benzoyl peroxide to induce skin irritation, such as erythema, burning and stinging. If approved, Epsolay has the potential to be the first FDA-approved single-active benzoyl peroxide prescription drug product. Epsolay is not approved by the FDA and the safety and efficacy has not been established. About Papulopustular Rosacea Papulopustular rosacea is a chronic and recurrent inflammatory skin disorder that affects nearly 5 million Americans. The condition is common, especially in fair-skinned people of Celtic and northern European heritage. Onset is usually after age 30 and typically begins as flushing and subtle redness on the cheeks, nose, chin or forehead. If left untreated, rosacea can slowly worsen over time. As the condition progresses the redness becomes more persistent, blood vessels become visible and pimples often appear. Other symptoms may include burning, stinging, dry skin, plaques and skin thickening. About Twyneo® Twyneo is an investigational, fixed-dose combination of encapsulated benzoyl peroxide, 3%, and encapsulated tretinoin, 0.1%, cream for the treatment of acne vulgaris. If approved, it will be the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin, which are separately encapsulated in silica using Sol-Gel’s proprietary microencapsulation technology. Tretinoin and benzoyl peroxide are widely prescribed separately as a combination treatment for acne; however, benzoyl peroxide causes degradation of the tretinoin molecule, thereby potentially reducing its effectiveness if used at the same time or combined in the same formulation. The silica-based microcapsule is designed to protect tretinoin from oxidative decomposition by benzoyl peroxide, thereby enhancing the stability of the active drug ingredients. The silica-based shell is also designed to release the ingredients slowly over time to provide a favorable efficacy and safety profile. Twyneo is not approved by the FDA and the safety and efficacy has not been established. About Acne Vulgaris Acne vulgaris is a common multifactorial skin disease that according to the American Academy of Dermatology affects approximately 40 to 50 million people in the United States. The disease occurs most frequently during childhood and adolescence (affecting 80% to 85% of all adolescents) but it may also appear in adults. Acne patients suffer from the appearance of lesions on areas of the body with a large concentration of oil glands, such as the face, chest, neck and back. These lesions can be inflamed (papules, pustules, nodules) or non-inflamed (comedones). Acne can have a profound effect on the quality of life of those suffering from the disease. In addition to carrying a substantial risk of permanent facial scarring, the appearance of lesions may cause psychological strain, social withdrawal and lowered self-esteem. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the PDUFA goal dates for Epsolay (benzoyl peroxide, 5%, cream) and Twyneo, the timing of commercialization of Epsolay and Twyneo, the timing and expected launch of an FDA-approved generic drug in the second quarter of 2021, and the timing of the Phase 1 data readout of SGT-210. These forward-looking statements include information about possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management’s current expectation and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, risks relating to the effects of COVID-19 (coronavirus) as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, Europe or Israel; and (xv) loss or retirement of key executives and research scientists. These and other important factors discussed in the Company's Annual Report on Form 20-F to be filed with the Securities and Exchange Commission (“SEC”) on March 4, 2021 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we undertake no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements. SOL-GEL TECHNOLOGIES LTD. CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) December 31 Assets 2019 2020 CURRENT ASSETS: Cash and cash equivalents $ 9,412 $ 7,122 Bank deposits - 21,400 Marketable securities 40,966 21,652 Receivables from collaborative arrangements 4,120 2,153 Prepaid expenses and other current assets 1,293 1,074 TOTAL CURRENT ASSETS 55,791 53,401 NON-CURRENT ASSETS: Restricted long-term deposits and cash 472 1,293 Property and equipment, net 2,314 1,817 Operating lease right-of-use assets 2,040 1,896 Funds in respect of employee rights upon retirement 684 754 TOTAL NON-CURRENT ASSETS 5,510 5,760 TOTAL ASSETS $ 61,301 $ 59,161 Liabilities and shareholders' equity CURRENT LIABILITIES: Accounts payable $ 1,710 $ 1,203 Other accounts payable 4,123 4,088 Current maturities of operating leases 672 673 TOTAL CURRENT LIABILITIES 6,505 5,964 LONG-TERM LIABILITIES: Operating leases liabilities 1,373 1,299 Liability for employee rights upon retirement 958 1,049 TOTAL LONG-TERM LIABILITIES 2,331 2,348 COMMITMENTS TOTAL LIABILITIES 8,836 8,312 SHAREHOLDERS' EQUITY: Ordinary shares, NIS 0.1 par value – authorized: 50,000,000 as of December 31, 2019 and 2020, respectively; issued and outstanding: 20,402,800 and 23,000,782 as of December 31, 2019 and December 31, 2020, respectively 561 635 Additional paid-in capital 203,977 231,577 Accumulated deficit (152,073 ) (181,363 ) TOTAL SHAREHOLDERS' EQUITY 52,465 50,849 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 61,301 $ 59,161 SOL-GEL TECHNOLOGIES LTD. CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except share and per share data) Year ended December 31, 2018 2019 2020 COLLABORATION REVENUES $ 129 $ 22,904 $ 8,771 OPERATING EXPENSES Research and Development 28,146 40,578 27,913 General and Administrative 5,504 8,276 11,091 TOTAL OPERATING LOSS 33,521 25,950 30,233 FINANCIAL INCOME, net (1,318 ) (1,374 ) (943 ) LOSS BEFORE INCOME TAXES 32,203 24,576 29,290 INCOME TAXES - 33 - LOSS FOR THE YEAR $ 32,203 $ 24,609 $ 29,290 BASIC AND DILUTED LOSS PER ORDINARY SHARE $ 1.80 $ 1.26 $ 1.30 WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE 17,867,589 19,534,562 22,574,688 For further information, please contact: Sol-Gel Contact:Gilad MamlokChief Financial Officer+972-8-9313433 Investor Contact:Michael LevitanSolebury Troutemail@example.com Source: Sol-Gel Technologies Ltd.
On 3 March, Jayalalithaa’s former aide Sasikala announced her decision to quit politics – and public life.
The BSE Sensex closed at 50,846.08, falling by 598.57 points or 1.16 percent. Similarly, the NSE Nifty ended lower at 15,080.75, down by 164.85 points or 1.08 percent
Contract research organizations (CROs) are making significant advancements to modernize and speed clinical trials, according to new research report.
Dublin, March 04, 2021 (GLOBE NEWSWIRE) -- The "Polychlorotrifluoroethylene Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029" report has been added to ResearchAndMarkets.com's offering. The polychlorotrifluoroethylene market is set to reach US$ 795 million from around US$ 540 million in 2019. The market is expected to grow at the rate of 4% CAGR during the forecast period of 2021 to 2029. China continues to be the largest market in the world for PCTFE owing to its large network of manufacturing centers and pharmaceutical companies. PCTFE is a high performance thermoplastic with excellent water vapor barrier properties. It is crystal clear and non inflammable with good heat and chemical resistance and also features excellent melt processability. Covid 19 impact on the PCTFE market was limited in relation to other markets. This was due to its application in crucial segments such as aerospace and healthcare. There was no direct impact in concern to the demand or supply other than minor shutdown of production and sales operations across countries. However, other macro factors impacting the overall environment had a large role to play in minor downsizing of the market growth during the forecast period.Widening Application across Industries Promising Market Potential:There has been significant transition with respect to its application has led to increased market revenues over the years. PCTFE that was once just used for laminating polymers is now an effective moisture barrier fir blister packing used in pharmaceutical. Similarly PCTFE which was once mere industrial product used in valves, chemical tanks etc has taken a leap into consumer applications with its use in semiconductors, LCD panels, Teflon coated products and so on. The resins of polychlorotrifluoroethylene are witnessing strong demand due its application as moisture barrier coating used in drug manufacturing. It is important to note the growth of the end user industries - for instance drug manufacturing market valued at US $325 billion in 2019 and is expected to grow over a CAGR of 14% from 2021 to 2029. Similar is the case with refrigeration market and Cryogenic application that is driving the market for PCTFE. PCTFE's applications that have stretched across various industries such as electrical and electronics, aerospace, healthcare and others have led to consistent increase in market revenues across the globe.Pricing Factor Remains Major Concern for PCTFE Vs Other Polymers:There has been a constant demand for new polymers considering the commercial and performance gaps of conventional polymers such as polyether ether ketone (PEEK) and polytetrafluoroethylene (PTFE). PCTFE therefore, stands superior in some aspects in comparison to conventionally polymers. PCTFE is superior in terms of tensile strength, versatility while processing and offer stability across wide range of temperature. In the process of finalization of polymers for a certain application lot of commercial and application analysis is performed and price remains one of the significant factors that impact the decision. PCTFE is priced higher than PTFE however, in environment that requires dimensional stability across wide range of temperature PCTFE becomes uncompromisable.Large variety of Players Intensifying Market CompetitionThe level of competition among the market participants in this PCTFE market is significantly high. The nature of players includes big brands with multiple portfolio such as Honeywell to Akzo Nobel to niche players such as Chemours. Across timeline, there have been significant changes in the fluoropolymer market for instance Dupont spun of its fluoropolymer segment, which is now called as Chemours. 3M has stopped it production of KEL-F which is no longer available in the market. Therefore, there has been constant development in the market with changing dynamics of competitors. Such trends have resulted in the formation of niche and focused companies that cater to the need of specialized client base. Many companies are also focusing in strategic partnership to expand the product portfolio or to expand their market reach.Historical & Forecast PeriodThis research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029. Key questions answered in this report What are the key market segments in current scenario and in the future by product categoriesWhat are the key market segments in current scenario and in the future by regionsWhat is the key impact of Covid 19 over market revenues and market determinants in the PCTFE market?What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?How to overcome the current market challenges and leverage the opportunities in each of the market segment?Who are the key players in the PCTFE market and what are their key product categories and strategies?What are the key strategies - mergers/acquisitions/R&D/strategic partnerships etc that companies are deploying to enhance market revenues and growth? Key Topics Covered: 1. Preface1.1. Report Description1.1.1. Purpose of the Report1.1.2. Target Audience1.1.3. USP and Key Product1.2. Research Scope1.3. Research Methodology1.3.1. Phase I - Secondary Research1.3.2. Phase II - Primary Research1.3.3. Phase III - Expert Panel Review1.3.4. Approach Adopted188.8.131.52. Top-Down Approach184.108.40.206. Bottom-Up Approach1.3.5. Assumptions1.4. Market Segmentation1.5 Post Covid Impact1.5.1 Economic analysis by geographic reason1.5.2 Key parametric analysis of factor impacting the market post covid191.5.3 Mitigation strategies of Covid 19 and impact on the market1.5.4 Estimation analysis- Precovid versus Post Covid2. Executive Summary2.1. Market Snapshot: Global Polychlorotrifluoroethylene (PCTFE) Market2.2. Global PCTFE Market, by Application, 2019 (US$ Mn)2.3. Global PCTFE Market, by End-use, 2019 (US$ Mn)2.4. Global PCTFE Market, by Geography, 2019 (US$ Mn)3. Market Dynamics3.1. Introduction3.1.1. Global PCTFE Market Value, 2019-2029, (US$ Mn)3.2. Market Dynamics3.2.1. Market Drivers3.2.2. Market Restraints3.3. Attractive Investment Proposition, by Geography, 20193.4. Market Positioning of Key Players, 20193.4.1. Major Strategies Adopted by Key Players4. Global Polychlorotrifluoroethylene (PCTFE) Market, by Application, 2019-2029(US$ Mn)4.1. Overview4.2. Films4.3. Wires & Tubes4.4. Coatings5. Global Polychlorotrifluoroethylene (PCTFE) Market, by End-use, 2019-2029(US$ Mn)5.1. Overview5.2. Pharmaceutical5.3. Electrical & Electronics5.4. Aerospace5.5. Others6. North America Polychlorotrifluoroethylene (PCTFE) Market Analysis, 2019-2029(US$ Mn)6.1. Overview6.1.1. North America PCTFE Market Value and Growth, 2019-2029, (US$ Mn)6.2. North America PCTFE Market Value, By Application, 2019-2029(US$ Mn)6.2.1. Market Analysis6.3. North America PCTFE Market Value, By End-use, 2019-2029(US$ Mn)6.3.1. Market Analysis6.4. North America PCTFE Market Value, By Region/Country, 2019-2029(US$ Mn)6.4.1. Market Analysis6.4.2. U.S.6.4.3. Rest of North America7. Europe Polychlorotrifluoroethylene (PCTFE) Market Analysis, 2019-2029(US$ Mn)7.1. Overview7.1.1. Europe PCTFE Market Value and Growth, 2019-2029, (US$ Mn)7.2. Europe PCTFE Market Value, By Application, 2019-2029(US$ Mn)7.2.1. Market Analysis7.3. Europe PCTFE Market Value, By End-use, 2019-2029(US$ Mn)7.3.1. Market Analysis7.4. Europe PCTFE Market Value, By Region/Country, 2019-2029(US$ Mn)7.4.1. Market Analysis7.4.2. U.K.7.4.3. Germany7.4.4. France7.4.5. Rest of Europe8. Asia Pacific Polychlorotrifluoroethylene (PCTFE) Market Analysis, 2019-2029(US$ Mn)8.1. Overview8.1.1. Asia Pacific PCTFE Market Value and Growth, 2019-2029, (US$ Mn)8.2. Asia Pacific PCTFE Market Value, By Application, 2019-2029(US$ Mn)8.2.1. Market Analysis8.3. Asia Pacific PCTFE Market Value, By End-use, 2019-2029(US$ Mn)8.3.1. Market Analysis8.4. Asia Pacific PCTFE Market Value, By Region/Country, 2019-2029(US$ Mn)8.4.1. Market Analysis8.4.2. Japan8.4.3. China8.4.4. India8.4.5. Rest of Asia Pacific9. Rest of the World Polychlorotrifluoroethylene (PCTFE) Market Analysis, 2019-2029(US$ Mn)9.1. Overview9.1.1. Rest of the World PCTFE Market Value and Growth, 2019-2029, (US$ Mn)9.2. Rest of the World PCTFE Market Value, By Application, 2019-2029(US$ Mn)9.2.1. Market Analysis9.3. Rest of the World PCTFE Market Value, By End-use, 2019-2029(US$ Mn)9.3.1. Market Analysis9.4. Rest of the World PCTFE Market Value, By Region, 2019-2029(US$ Mn)9.4.1. Market Analysis9.4.2. Middle East & Africa9.4.3. Latin America10. Company Profiles10.1. Daikin10.2. Honeywell10.3. DuPont10.4. Arkema10.5. Solvay10.6. Akzonobel10.7. Chemours10.8. SABIC10.9. Fluorocarbon Company Ltd10.10. Lima Srl For more information about this report visit https://www.researchandmarkets.com/r/8f5n5w CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The "Cold Storage Construction - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
LONDON — Prince Philip has had a successful heart procedure at a London hospital and is expected to remain for several days of “rest and recuperation,” Buckingham Palace said Thursday. The palace said the 99-year-old husband of Queen Elizabeth II “underwent a successful procedure for a pre-existing heart condition at St Bartholomew’s Hospital.” “His royal highness will remain in hospital for treatment, rest and recuperation for a number of days,'' the palace said in a statement. Philip, 99, has been hospitalized since being admitted to King Edward VII’s Hospital in London on Feb. 16, where he was treated for an infection. On Monday he was transferred to a specialized cardiac care hospital, St. Bartholomew’s. Camilla, Duchess of Cornwall, said Wednesday that Philip's condition was “slightly improving.” “We’ll keep our fingers crossed," said Camilla, who is married to Prince Charles, eldest son of Philip and the queen. Philip's illness is not believed to be related to the coronavirus. Both Philip and the monarch received COVID-19 vaccinations in January and chose to publicize the matter to encourage others to also take the vaccine. Philip, also known as the Duke of Edinburgh, retired in 2017 and rarely appears in public. Before his hospitalization, Philip had been isolating at Windsor Castle, west of London, with the queen. Although he enjoyed good health well into old age, Philip has had heart issues in the past. In 2011, he was rushed to a hospital by helicopter after suffering chest pains and was treated for a blocked coronary artery. The longest-serving royal consort in British history, Philip married the then-Princess Elizabeth in 1947. He and the queen have four children, eight grandchildren and nine great-grandchildren. His illness comes as the royal family braces for the broadcast of an interview conducted by Oprah Winfrey with Meghan, Duchess of Sussex. Meghan and husband Prince Harry quit royal duties last year and moved to California, citing what they said were the unbearable intrusions and racist attitudes of the British media. Relations between the couple and the palace appear to have become increasingly strained. On Wednesday, the palace said it was launching a human resources investigation after a newspaper reported that a former aide had accused Meghan of bullying staff in 2018. In a clip from the pre-recorded Winfrey interview, released by CBS, Winfrey asks Meghan how she feels about the palace “hearing you speak your truth today?” “I don’t know how they could expect that after all of this time we would still just be silent if there was an active role that the firm is playing in perpetuating falsehoods about us,” the duchess says. “The Firm” is a nickname for the royal family, sometimes used with affection and sometimes with a note of criticism. Jill Lawless And Danica Kirka, The Associated Press
The regulatory approach to new vaccines will be similar to the modified flu shot, which changes every year.
Also tonight, “Dateline” re-airs its episode on Heather Elvis, a woman who went missing from Myrtle Beach in 2013.
The Delhi HC also asked the Centre to explain why only people of a certain age group were allowed to take vaccines.
Southfield, MI, March 04, 2021 (GLOBE NEWSWIRE) -- Sun Communities, Inc. (NYSE:SUI) (the “Company”), a real estate investment trust (“REIT”) that owns and operates or has an interest in manufactured housing communities, recreational vehicle resorts and marinas, today announced that it has commenced an underwritten public offering of an aggregate of 7,000,000 shares of its common stock, consisting of 4,000,000 shares offered directly by the Company and 3,000,000 shares offered on a forward basis in connection with the forward sale agreement described below. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock. The Company expects to enter into a forward sale agreement with Citibank, N.A. (the “Forward Purchaser”) with respect to 3,000,000 shares of its common stock (or an aggregate of 4,050,000 shares if the underwriters exercise their option to purchase additional shares in full). In connection with the forward sale agreement, the Forward Purchaser or its affiliates are expected to borrow and sell to the underwriters an aggregate of 3,000,000 shares of the common stock that will be delivered in this offering (or an aggregate of 4,050,000 shares if the underwriters exercise their option to purchase additional shares in full). Subject to the Company’s right to elect cash or net share settlement, which right is subject to certain conditions, the Company intends to deliver, upon physical settlement of such forward sale agreement on one or more dates specified by the Company occurring no later than March 9, 2022, an aggregate of 3,000,000 shares of its common stock (or an aggregate of 4,050,000 shares if the underwriters exercise their option to purchase additional shares in full) to the Forward Purchaser in exchange for cash proceeds per share equal to the applicable forward sale price, which will be the public offering price, less underwriting discounts and commissions, and will be subject to certain adjustments as provided in the forward sale agreement. The Company will not initially receive any proceeds from the sale of shares of its common stock by the Forward Purchaser or its affiliates in the offering. The Company intends to use the net proceeds from the sale of 4,000,000 shares of common stock offered directly by the Company and the net proceeds, if any, received upon the future settlement of the forward sale agreement to repay borrowings outstanding under the revolving loan under the credit facility of its subsidiary Safe Harbor Marinas, LLC, to fund possible future acquisitions of properties and for working capital and general corporate purposes. Citigroup, BofA Securities, BMO Capital Markets, J.P. Morgan and RBC Capital Markets are acting as book-running managers for the offering. The offering will be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained by contacting Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146 or email to: Prospectus@citi.com); by contacting BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department or by email at email@example.com; by contacting BMO Capital Markets, 3 Times Square, 25th Floor, New York, NY 10036, Attention: Syndicate Department, Telephone: (800) 414-3627, or by email at firstname.lastname@example.org; by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (866) 803-9204 or by email at email@example.com; or by contacting RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; Phone: 877-822-4089; Email: firstname.lastname@example.org. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale is not permitted. Sun Communities, Inc. is a REIT that, as of December 31, 2020, owned, operated, or had an interest in a portfolio of 552 developed manufactured housing, recreational vehicle and marina properties comprising over 188,000 developed sites in 39 states and Ontario, Canada. Forward Looking Statements This press release contains various “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and the Company intends that such forward-looking statements will be subject to the safe harbors created thereby. Forward-looking statements can be identified by words such as “will,” “may,” “could,” “expect,” “anticipate,” “believes,” “intends,” “should,” “plans,” “estimates,” “approximate,” “guidance,” and similar expressions in this press release that predict or indicate future events and trends and that do not report historical matters. These forward-looking statements reflect the Company's current views with respect to future events and financial performance, but involve known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control. These risks, uncertainties, and other factors may cause the actual results of the Company to be materially different from any future results expressed or implied by such forward-looking statements. Such risks and uncertainties include the effects of the COVID-19 pandemic and related stay-at-home orders, quarantine policies and restrictions on travel, trade and business operations; national, regional and local economic climates; difficulties in the Company's ability to evaluate, finance, complete and integrate acquisitions, developments and expansions successfully; the ability to maintain rental rates and occupancy levels; competitive market forces; the performance of recent acquisitions; changes in market rates of interest; changes in foreign currency exchange rates; the ability of purchasers of manufactured homes and boats to obtain financing; and the level of repossessions by manufactured home lenders. Further details of potential risks that may affect the Company are described in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission, including in the “Risk Factors” sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2020. The forward-looking statements contained in this press release speak only as of the date hereof and the Company expressly disclaims any obligation to provide public updates, revisions or amendments to any forward-looking statements made herein to reflect changes in the Company's assumptions, expectations of future events, or trends. For Further Information at the Company:Karen J. DearingChief Financial Officer (248) 208-2500 www.suncommunities.com
GATC Health's agreement with Cannaponics will allow them to offer GATC's genetics-based medical cannabis test to physicians and their patients.
– Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 – – On track to report results from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2021 – – Company to discontinue Phase 3 COVID-19 trial (LOSVID) – – Extended cash runway into 4Q 2022; raised $50.6 million in gross proceeds from January 2021 public offering – – Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2020. “In 2020, we made meaningful progress in advancing our pipeline despite the extraordinary challenges brought on by COVID-19,” said Robert J. Gould, Ph.D., president and chief executive officer. “We have laid the foundation to achieve several key milestones in 2021, including a comprehensive assessment of our Phase 2 ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy late in the second quarter and completing our Phase 1 trial in healthy adult volunteers with FTX-6058, a highly potent small molecule EED inhibitor in development for the treatment of select hemoglobinopathies, including sickle cell disease and beta-thalassemia. Additionally, after careful consideration and a strategic review of the COVID-19 landscape, we are discontinuing our LOSVID trial. This enables us to focus on rare diseases. I would like to thank the patients and investigators who participated in this trial and the Fulcrum team who worked tirelessly to rapidly design and launch the LOSVID trial during a global pandemic.” “Furthermore, we have made great progress with our next-generation product engine including new levels of validation in our internal research efforts and externally through our strategic collaborations,” continued Dr. Gould. “With the additional capital from our recent public offering, we have extended our cash runway into the fourth quarter of 2022 and we believe that we are well positioned to continue progress on our goal to advance therapies to improve the lives of patients with genetically defined rare diseases.” Recent Business Highlights On track to report data from ReDUX4, a Phase 2b trial of losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor, in FSHD late in the second quarter of 2021. Data will include the primary endpoint, reduction from baseline of DUX4-driven gene expression, as well as a pre-specified sensitivity analysis assessing biopsies with the highest pre-treatment level of DUX4-driven gene expression. Additionally, secondary endpoints, including skeletal muscle MRI and exploratory endpoints, including clinical outcome assessments and patient reported outcomes will also be reported.Continued evaluation of the Phase 2 Open Label Study. On track to report results from the Phase 1 trial in healthy adult volunteers with FTX-6058 in development for sickle cell disease (SCD) in mid-2021, and to begin dosing patients with SCD by year end. FTX-6058, a highly potent small molecule EED inhibitor, is designed to induce expression of fetal hemoglobin (HbF) in red blood cells following oral administration to compensate for the mutated adult hemoglobin associated with hemoglobinopathies, including sickle cell disease and beta-thalassemia.Preclinical data with FTX-6058 showed an increase in HbF levels up to approximately 30% of total hemoglobin, indicating the potential to have a significant impact on patients with sickle cell disease. After careful consideration, Fulcrum is discontinuing LOSVID, a Phase 3 trial with losmapimod for hospitalized subjects with COVID-19, due to significant changes in the COVID-19 treatment paradigm, including new therapeutic options and emerging vaccines. The company has decided to redeploy its resources to other clinical programs and discovery efforts, with a continued focus on rare diseases.Losmapimod was generally well tolerated in LOSVID, and an independent data safety monitoring board did not identify any safety concerns related to losmapimod. Multiple scientific meeting presentations Presentation on FulcrumSeek, the company’s next generation product engine approach, at the Society for Laboratory Automation and Screening annual meeting in January 2021.Presented multiple posters supporting the potential of FTX-6058 in sickle cell disease at the 62nd American Society of Hematology (ASH) annual meeting, December 5-8, 2020.Presented target engagement and good tolerability with FTX-6058 in multiple preclinical rodent models with once-a-day oral dosing at the 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting, September 25, 2020.Presented multiple posters supporting Fulcrum’s integrated approach to the evaluation of FSHD patients during the 25th International Congress of the World Muscle Society (WMS), October 1, 2020. Advanced FulcrumSeek discovery efforts and strategic collaborations with Acceleron and MyoKardia, a wholly owned subsidiary of Bristol-Myers Squibb Company. Raised gross proceeds of $50.6 million from a public offering in January 2021. The underwritten public offering of 4,600,000 shares of the company’s common stock at a public offering price of $11.00 per share included 600,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price. Key management updates CEO transition: On March 4, 2021, Fulcrum announced that Bryan E. Stuart will be promoted to president and chief executive officer and Robert J. Gould, Ph.D. will retire from his role as president and chief executive officer, each effective March 31, 2021. Mr. Stuart has also been appointed to Fulcrum’s Board of Directors. Dr. Gould will continue to serve on Fulcrum’s Board and has also been appointed to the Scientific & Technology committee of the Board. Additionally, Mark Levin, Fulcrum’s Board chair, will assume the role of executive chair effective upon Dr. Gould’s retirement.CSO transition: On January 19, 2021, Fulcrum announced that Chris Moxham, Ph.D. was promoted to chief scientific officer and Owen Wallace, Ph.D. stepped down from his role as chief scientific officer, each effective February 5, 2021. Dr. Wallace has been appointed to Fulcrum’s Scientific Advisory Board. Fourth Quarter and Full Year 2020 Financial Results Cash Position: As of December 31, 2020, cash, cash equivalents, and marketable securities were $112.9 million, as compared to $96.7 million as of December 31, 2019. Based on current plans, the company expects that its cash, cash equivalents, and marketable securities as of December 31, 2020, together with the net proceeds of $46.4 million from the sale of its common stock in a public offering on January 22, 2021, will be sufficient to enable Fulcrum to fund operating expenses and capital expenditure requirements into the fourth quarter of 2022. Collaboration Revenue: Collaboration revenue was $4.2 million for the fourth quarter of 2020, as compared to no revenue recognized during the fourth quarter of 2019. The increase in collaboration revenue was due to the execution of the company’s collaboration and license agreements with Acceleron and MyoKardia in December 2019 and July 2020, respectively.Collaboration revenue was $8.8 million for the year ended December 31, 2020, as compared to no revenue recognized during the year ended December 31, 2019. The increase in collaboration revenue was due to the execution of the collaboration and license agreements with Acceleron and MyoKardia in December 2019 and July 2020, respectively. R&D Expenses: Research and development expenses were $16.1 million for the fourth quarter of 2020, as compared to $12.1 million for the fourth quarter of 2019. The increase of $4.0 million was primarily due to increased costs to support the company’s ongoing and planned clinical trials and increased personnel-related costs to support the growth of Fulcrum’s research and development organization, including increased stock-based compensation expense.Research and development expenses were $59.0 million for the year ended December 31, 2020, as compared to $71.1 million for the year ended December 31, 2019. Research and development expenses for the year ended December 31, 2019 include $25.6 million of one-time costs incurred associated with the issuance of Series B convertible preferred stock under the company’s license agreement with GSK for losmapimod and $2.5 million of one-time costs incurred associated with the achievement of a milestone under the company’s license agreement with GSK for losmapimod. Excluding these one-time costs, the increase of $16.0 million was primarily due to increased costs to support the company’s ongoing and planned clinical trials and increased personnel-related costs to support the growth of Fulcrum’s research and development organization, including increased stock-based compensation expense. G&A Expenses: General and administrative expenses were $5.9 million for the fourth quarter of 2020, as compared to $4.4 million for the fourth quarter of 2019. The increase of $1.5 million was primarily due to increased costs associated with operating as a public company and increased personnel-related costs to support the growth of the organization, including increased stock-based compensation expense.General and administrative expenses were $21.4 million for the year ended December 31, 2020, as compared to $13.1 million for the year ended December 31, 2019. The increase of $8.3 million was primarily due to increased costs associated with operating as a public company and increased personnel-related costs to support the growth of the organization, including increased stock-based compensation expense. Net Loss: Net loss was $17.7 million for the fourth quarter of 2020, as compared to a net loss of $16.1 million for the fourth quarter of 2019.Net loss was $70.8 million for the year ended December 31, 2020, as compared to $82.7 million for the year ended December 31, 2019. Conference Call and WebcastFulcrum Therapeutics, Inc. will host a conference call and webcast today at 8:00 a.m. ET to discuss the company’s fourth quarter and full year 2020 financial results and recent business highlights. The webcast will be accessible through the Investor Relations section of Fulcrum’s website at www.fulcrumtx.com. Following the live webcast, an archived replay will also be available. Dial-in NumberU.S./Canada Dial-in Number: 800-527-6973International Dial-in Number: 470-495-9162Conference ID: 6376419 Replay Dial-in Number: 855-859-2056Replay International Dial-in Number: 404-537-3406Conference ID: 6376419 About FSHD FSHD is characterized by progressive skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms and trunk, and progresses to weakness throughout the lower body. Skeletal muscle weakness results in significant physical limitations, including an inability to smile and difficulty using arms for activities, with many patients ultimately becoming dependent upon the use of a wheelchair for daily mobility. FSHD is caused by mis-expression of DUX4 in skeletal muscle, resulting in the presence of DUX4 proteins that are toxic to muscle tissue. Normally, DUX4-driven gene expression is limited to early embryonic development, after which time the DUX4 gene is silenced. In people with FSHD, the DUX4 gene is turned “on” as a result of a genetic mutation. The result is death of muscle and its replacement by fat, leading to skeletal muscle weakness and progressive disability. There are no approved therapies for FSHD, one of the most common forms of muscular dystrophy, with an estimated patient population of 16,000 to 38,000 in the United States alone. About Losmapimod Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor that was exclusively in-licensed from GSK by Fulcrum Therapeutics following Fulcrum’s discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Utilizing its internal product engine, Fulcrum discovered that inhibition of p38α/β reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD. Losmapimod has been evaluated in more than 3,600 subjects in clinical research across multiple indications, including in several Phase 2 trials and a large Phase 3 trial in acute myocardial infarction. No safety signals were attributed to losmapimod in any of these trials. In 2020, the company received U.S. and European Orphan Drug Designation for losmapimod for the treatment of FSHD. Fulcrum is currently conducting Phase 2 trials investigating the safety, tolerability, and efficacy of losmapimod to treat the root cause of FSHD. About Sickle Cell Disease Sickle cell disease (SCD) is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. The result of the mutation is less efficient oxygen transport and the formation of red blood cells that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels or rupture cells. SCD patients typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease and reduced life expectancy. About FTX-6058 FTX-6058 is a highly potent small molecule inhibitor of Embryonic Ectoderm Development (EED) capable of inducing robust HbF protein expression in cell and murine models. Fulcrum believes the pharmacokinetics and human dose simulations support that FTX-6058 may be given as a once daily oral compound. The validation of EED as a target for sickle cell disease and the discovery of FTX-6058 as a novel HbF-inducing small molecule were conducted using Fulcrum’s proprietary product engine. Preclinical data with FTX-6058 showed an increase in HbF levels up to approximately 30% of total hemoglobin. Fulcrum has initiated a Phase 1 trial with FTX-6058 in healthy adult volunteers. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development. Please visit www.fulcrumtx.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company’s product candidates, the potential advantages and therapeutic potential of Fulcrum’s product candidates, initiation and enrollment of clinical trials and availability of clinical trial data, and the Company’s ability to fund its operations with cash on hand. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company’s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Fulcrum’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in clinical trials; initiate and enroll clinical trials on the timeline expected or at all; correctly estimate the potential patient population and/or market for the Company’s product candidates; replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of losmapimod, FTX-6058 and its other product candidates; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. Fulcrum Therapeutics, Inc. Selected Consolidated Balance Sheet Data (In thousands) (Unaudited) December 31,2020 December 31,2019 Cash, cash equivalents, and marketable securities$112,914 $96,713 Working capital(1) 92,785 87,943 Total assets 129,577 110,439 Total stockholders’ equity 95,181 87,153 (1) We define working capital as current assets minus current liabilities. Fulcrum Therapeutics, Inc. Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) Three Months EndedDecember 31, Year EndedDecember 31, 2020 2019 2020 2019 Collaboration revenue$4,225 $— $8,823 $— Operating expenses: Research and development 16,145 12,087 59,042 71,072 General and administrative 5,867 4,403 21,392 13,145 Total operating expenses 22,012 16,490 80,434 84,217 Loss from operations (17,787) (16,490) (71,611) (84,217)Other income, net 67 367 792 1,540 Net loss$(17,720) $(16,123) $(70,819) $(82,677)Cumulative convertible preferred stock dividends — — — (7,128)Net loss attributable to common stockholders$(17,720) $(16,123) $(70,819) $(89,805)Net loss per share attributable to common stockholders, basic and diluted$(0.64) $(0.71) $(2.79) $(8.13)Weighted average number of common shares used in net loss per share attributable to common stockholders, basic and diluted 27,537 22,610 25,354 11,046 Contact: Investors: Christi Waarich Director, Investor Relations and Corporate Communicationscwaarich@fulcrumtx.com617-651-8664 Stephanie Ascher Stern Investor Relations, Inc.email@example.com Media: Kaitlin GallagherBerry & Company Public Relationskgallagher@berrypr.com212-253-8881
Schrödinger today reported financial results for the fourth quarter and full year 2020.
Shift4 Payments (NYSE: FOUR), the leader in integrated payment processing solutions, has posted its fourth quarter and full year 2020 financial results as part of its 4Q 2020 shareholder letter under the Financials section of its Investor Relations website at https://investors.shift4.com/overview/default.aspx.
Mastercard SpendingPulse: U.S. retail sales grow 4.6% in February despite winter blast. Another big month for e-commerce, which increased 54.7% YOY.